CombiGene has entered into a collaboration agreement with Danish Zyneyro regarding the continued development of treatments for chronic pain conditions – a peptide with short-term benefits and a gene therapy with potentially lifelong effects. To find out more about what sparked CombiGene’s interest in Zyneyro and their projects in temporary and chronic pain conditions, BioStock contacted CombiGene’s CEO Jan Nilsson.
Read more here; https://www.biostock.se/en/2023/01/chronic-pain-in-focus-for-combigenes-new-collaboration/